Iterum Therapeutics regains Nasdaq compliance, hearing cancelled

Iterum Therapeutics plc

Nasdaq confirmed Iterum cured its Listing Rule 5550(b) deficiency; previously scheduled Nov 21 hearing cancelled.
Company will continue trading on Nasdaq Capital Market; avoids potential delisting.
CEO Corey Fishman expressed commitment to adhere to listing requirements.

item 8.01 item 9.01

Iterum Therapeutics plc filing history →

Source: SEC EDGAR

accession 0000950170-24-129507

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.